Derek J. Maetzold Sells 2,368 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) Stock

Castle Biosciences, Inc. (NASDAQ:CSTLGet Free Report) insider Derek J. Maetzold sold 2,368 shares of Castle Biosciences stock in a transaction that occurred on Monday, May 6th. The stock was sold at an average price of $24.72, for a total value of $58,536.96. Following the completion of the transaction, the insider now directly owns 62,629 shares in the company, valued at $1,548,188.88. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Castle Biosciences Price Performance

Shares of CSTL stock opened at $24.42 on Friday. The stock’s fifty day simple moving average is $20.81 and its 200 day simple moving average is $20.61. Castle Biosciences, Inc. has a one year low of $9.26 and a one year high of $26.70. The firm has a market cap of $674.24 million, a price-to-earnings ratio of -21.23 and a beta of 0.93. The company has a debt-to-equity ratio of 0.02, a current ratio of 9.25 and a quick ratio of 9.02.

Castle Biosciences (NASDAQ:CSTLGet Free Report) last issued its earnings results on Wednesday, February 28th. The company reported ($0.10) EPS for the quarter, beating the consensus estimate of ($0.84) by $0.74. Castle Biosciences had a negative net margin of 12.28% and a negative return on equity of 7.91%. The company had revenue of $66.12 million for the quarter, compared to the consensus estimate of $51.32 million. On average, analysts expect that Castle Biosciences, Inc. will post -2.41 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. BluePath Capital Management LLC acquired a new position in shares of Castle Biosciences during the 3rd quarter worth about $31,000. RiverPark Advisors LLC increased its stake in shares of Castle Biosciences by 362.2% in the first quarter. RiverPark Advisors LLC now owns 2,861 shares of the company’s stock valued at $63,000 after buying an additional 2,242 shares during the period. Assetmark Inc. raised its position in shares of Castle Biosciences by 34.2% during the 3rd quarter. Assetmark Inc. now owns 3,904 shares of the company’s stock valued at $66,000 after buying an additional 994 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its stake in shares of Castle Biosciences by 351.4% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 3,110 shares of the company’s stock valued at $67,000 after buying an additional 2,421 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Castle Biosciences by 74.8% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,797 shares of the company’s stock worth $115,000 after buying an additional 2,909 shares during the period. Institutional investors and hedge funds own 92.60% of the company’s stock.

Wall Street Analyst Weigh In

CSTL has been the topic of a number of research reports. Scotiabank boosted their target price on shares of Castle Biosciences from $33.00 to $37.00 and gave the stock a “sector outperform” rating in a research report on Friday, March 1st. KeyCorp raised their target price on Castle Biosciences from $25.00 to $28.00 and gave the stock an “overweight” rating in a research report on Friday, March 1st. Finally, Robert W. Baird increased their price objective on shares of Castle Biosciences from $33.00 to $34.00 and gave the company an “outperform” rating in a research note on Friday, May 3rd.

Read Our Latest Stock Report on Castle Biosciences

About Castle Biosciences

(Get Free Report)

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.

Featured Articles

Insider Buying and Selling by Quarter for Castle Biosciences (NASDAQ:CSTL)

Receive News & Ratings for Castle Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Castle Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.